Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NRG Oncology
City of Hope Medical Center
University of Texas Southwestern Medical Center
University Health Network, Toronto
University of Michigan Rogel Cancer Center
NRG Oncology
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
Mayo Clinic
National Cancer Institute (NCI)
Children's Oncology Group
Washington University School of Medicine
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Children's Oncology Group
University of Iowa
Mayo Clinic
Washington University School of Medicine
NRG Oncology
NRG Oncology
Ohio State University Comprehensive Cancer Center
Sun Yat-sen University
The Cleveland Clinic
Case Comprehensive Cancer Center
First Affiliated Hospital of Fujian Medical University
GOG Foundation
New Mexico Cancer Research Alliance
Thomas Jefferson University
Thomas Jefferson University
NRG Oncology
University of Texas Southwestern Medical Center
Stanford University
National Cancer Institute (NCI)
Ann & Robert H Lurie Children's Hospital of Chicago
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
University of California, San Diego
Hackensack Meridian Health
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute, Naples
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Wake Forest University Health Sciences
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Emory University
Menoufia University
Case Comprehensive Cancer Center